Brandon A Carter-Cooper
Overview
Explore the profile of Brandon A Carter-Cooper including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Miguel-Perez D, Russo A, Gunasekaran M, Buemi F, Hester L, Fan X, et al.
Cancer
. 2022 Dec;
129(4):521-530.
PMID: 36484171
Background: Immune-checkpoint inhibitors (ICIs) are an effective therapeutic strategy, improving the survival of patients with lung cancer compared with conventional treatments. However, novel predictive biomarkers are needed to stratify which...
2.
Dayal N, Mikek C, Hernandez D, Naclerio G, Chu E, Carter-Cooper B, et al.
Eur J Med Chem
. 2019 Jul;
180:449-456.
PMID: 31330446
Rho-associated protein kinases (ROCKs) are ubiquitously expressed in most adult tissues, and are involved in modulating the cytoskeleton, protein synthesis and degradation pathways, synaptic function, and autophagy to list a...
3.
Yang Z, Liao J, Carter-Cooper B, Lapidus R, Cullen K, Dan H
BMC Cancer
. 2019 May;
19(1):485.
PMID: 31118072
Background: We investigated the role of the ETS-1 transcription factor in Head and Neck Squamous Cell Carcinoma (HNSCC) in multiple cisplatin-resistant HNSCC cell lines. Methods: We examined its molecular link...
4.
Adige S, Lapidus R, Carter-Cooper B, Duffy A, Patzke C, Law J, et al.
Cancer Chemother Pharmacol
. 2019 Apr;
83(6):1105-1112.
PMID: 30968179
In the treatment of acute myeloid leukemia (AML), the "7 + 3"-based strategy, combining cytarabine 100-200 mg/m for 7 days with an anthracycline for 3 days, remains the standard of...
5.
Naganna N, Opoku-Temeng C, Choi E, Larocque E, Chang E, Carter-Cooper B, et al.
EBioMedicine
. 2019 Jan;
40:231-239.
PMID: 30686755
Background: Acute myeloid leukemia (AML) remains one of the most lethal, rarely cured cancers, despite decades of active development of AML therapeutics. Currently, the 5-year survival of AML patients is...
6.
Dayal N, Opoku-Temeng C, Hernandez D, Sooreshjani M, Carter-Cooper B, Lapidus R, et al.
Future Med Chem
. 2018 Feb;
10(7):823-835.
PMID: 29437468
Aim: Approximately 30% of acute myeloid leukemia (AML) patients carry FLT3 tyrosine kinase domain (TKD) mutations or internal tandem duplication (FLT3-ITD). Currently there is a paucity of compounds that are...
7.
Emadi A, Law J, Strovel E, Lapidus R, Jeng L, Lee M, et al.
Cancer Chemother Pharmacol
. 2017 Nov;
81(1):217-222.
PMID: 29119293
Depletion of glutamine (Gln) has emerged as a potential therapeutic approach in the treatment of acute myeloid leukemia (AML), as neoplastic cells require Gln for synthesis of cellular components essential...
8.
Carter-Cooper B, Fletcher S, Ferraris D, Choi E, Kronfli D, Dash S, et al.
Bioorg Med Chem Lett
. 2016 Nov;
27(1):6-10.
PMID: 27890379
The synthesis, characterization and antileukemic activity of rationally designed amino dimeric naphthoquinone (BiQ) possessing aziridine as alkylating moiety is described. Bis-aziridinyl BiQ decreased proliferation of acute myeloid leukemia (AML) cell...
9.
Lapidus R, Carter-Cooper B, Sadowska M, Choi E, Wonodi O, Muvarak N, et al.
Pharmaceuticals (Basel)
. 2016 Jan;
9(1).
PMID: 26797621
Selective targeting of the oxidative state, which is a tightly balanced fundamental cellular property, is an attractive strategy for developing novel anti-leukemic chemotherapeutics with potential applications in the treatment of...
10.
Kondaskar A, Kondaskar S, Fishbein J, Carter-Cooper B, Lapidus R, Sadowska M, et al.
Bioorg Med Chem
. 2013 Jan;
21(3):618-31.
PMID: 23290252
Judicial structural modifications of 5:7-fused ring-expanded nucleosides (RENs), based on molecular modeling studies with one of its known targets, human RNA helicase (hDDX3), led to the lead, novel, 5:7-5-fused tricyclic...